-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Maintains Buy on UroGen Pharma, Raises Price Target to $45

Benzinga·05/11/2026 11:10:29
Listen to the news
HC Wainwright & Co. analyst Raghuram Selvaraju maintains UroGen Pharma (NASDAQ:URGN) with a Buy and raises the price target from $40 to $45.